BASi, INCAPS Enter Biomarker Alliance

INCAPS and BASi have entered a corporate alliance in which the two CROs will offer complementary services. INCAPS has a focus on proteomics and protein characterization studies using current and emerging technology platforms and BASi is focused on in-life safety and pharmacology assessment of new drug substances with a small molecule focus.

BASi chairman and chief executive officer Pete Kissinger commented, “INCAPS has assembled a first-rate team and state-of-the-art instrumentation, informatics and statistical analysis tailored toward discovery biology and biomarkers. This is an increasingly important part of what our clients require, and it is more advantageous for us to partner rather than add these resources to our own business. The geographic proximity of INCAPS to both our West Lafayette and Evansville laboratories is convenient, and we already have several common clients. This alliance is especially important for us because there is increased interest in monitoring the safety and effectiveness of drugs by examining proteomic responses to chronic and acute dosing. It’s all about understanding metabolic mechanisms.”

Dr. James Ludwig, chief executive officer of INCAPS added, “We are pleased to be able to offer our clients one-stop shopping for large- and small-molecule work. BASi has established themselves as a leader in bioanalytical chemistry services and we are delighted to be associated with them.”